About
ST Innovative Diagnostics developed a novel blood-based malignancy monitoring test, based on research from Rabin Medical Center and Tel Aviv University. The company's proprietary technology & kit, measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring and relapse prediction across multiple malignancies.
POC Clinical studies have shown high correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma. The technology shows promise for early detection of treatment resistance in NHL patients, facilitating timely transition to second-line therapies and preventing T-cell exhaustion and is planned to expand to solid tumor monitoring & diagnosis, including Metastatic Colorectal and Pancreatic Cancers.
Funding history · 1 round · $70K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of ST Innovative Diagnostics?
- ST Innovative Diagnostics focuses on developing a novel blood-based malignancy monitoring test to enable non-invasive disease monitoring and relapse prediction across multiple malignancies.
- What is the core technology behind ST Innovative Diagnostics' malignancy monitoring test?
- The company's proprietary technology and kit measure Fibrinogen Like Protein 2 (FGL2) activity in platelets.
- What clinical evidence supports ST Innovative Diagnostics' technology?
- Proof-of-concept clinical studies have shown a high correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma.
- What potential future applications does ST Innovative Diagnostics envision for its technology?
- ST Innovative Diagnostics plans to expand its technology for solid tumor monitoring and diagnosis, including Metastatic Colorectal and Pancreatic Cancers.
- When was ST Innovative Diagnostics founded?
- ST Innovative Diagnostics was founded in July 2022.
- What was ST Innovative Diagnostics' most recent funding activity?
- In July 2024, ST Innovative Diagnostics completed a SAFE round, raising $70,000.
- Who is a founder of ST Innovative Diagnostics?
- Esther Rabizadeh is a founder of ST Innovative Diagnostics.
- What is the current employee count for ST Innovative Diagnostics?
- ST Innovative Diagnostics currently has 2 employees.
- Has ST Innovative Diagnostics published any research related to its technology?
- Yes, a publication titled 'Presence and activity of Fibrinogen like protein 2 in platelets' was released on journals.plos.org on May 18, 2024.